Hematologic Malignancy
Myeloproliferative Chronic Myelomonocytic Leukemia
CI-CAN-00006082Explore in graph →
Hematologic1 active trials
- NCIt
- C203444
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006082Explore in graph →
Clinical trials
1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05365035 | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 5, 2026source: clinicaltrials